TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, Garcia-Manero G, Kantarjian H, Chen R, Stone RM, Neuberg D, Steensma DP, Ebert BL.
Bejar R, et al. Among authors: lord a.
Blood. 2014 Oct 23;124(17):2705-12. doi: 10.1182/blood-2014-06-582809. Epub 2014 Sep 15.
Blood. 2014.
PMID: 25224413
Free PMC article.